Modality
Multispecific
MOA
EGFRi
Target
KRASG12D
Pathway
Cell Cycle
Heart FailureGBMMeso
Development Pipeline
Preclinical
~Mar 2016
→ ~Jun 2017
Phase 1
Sep 2017
→ Oct 2031
Phase 1Current
NCT08030625
463 pts·GBM
2017-09→2026-03·Completed
NCT05549249
2,527 pts·Meso
2021-11→2031-10·Active
2,990 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-03-162w agoPh2 Data· GBM
2031-10-125.5y awayPh2 Data· Meso
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P1/2
Complet…
P1/2
Active
Catalysts
Ph2 Data
2026-03-16 · 2w ago
GBM
Ph2 Data
2031-10-12 · 5.5y away
Meso
ActiveCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08030625 | Phase 1/2 | GBM | Completed | 463 | CfB |
| NCT05549249 | Phase 1/2 | Meso | Active | 2527 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Niranesiran | Johnson & Johnson | Phase 2 | KIF18A | |
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| SNY-2934 | Sanofi | Phase 3 | KRASG12D | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| GSK-2051 | GSK | Phase 1 | PSMA | |
| GIL-2037 | Gilead Sciences | Approved | KRASG12D | |
| GIL-8529 | Gilead Sciences | Phase 1/2 | JAK1 | |
| NBI-408 | Neurocrine | Phase 2/3 | KRASG12D |